Strides Says Forsteo Biosimilar ‘Significant Product’, Seeks New Minority Investor In Stelis
Cuts Stake In Kenyan Venture To 49%
Executive Summary
Strides sees Kauliv, a biosimilar to Eli Lilly’s Forsteo, as a ‘significant’ but ‘not a massive product’ as it prepares to register it in multiple countries post a positive opinion from EMA. Meanwhile, more clarity on fund raising for Stelis is expected by March 2023 even as the regulatory timeline for a COVID-19 vaccine from Akston is extended by 2-3 months